Akebia Therapeutics (United States)

Akebia Therapeutics is a biopharmaceutical company focused on developing innovative therapies for kidney disease. Headquartered in Cambridge, Massachusetts, Akebia developed Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for treating anemia associated with chronic kidney disease (CKD). The company addresses unmet needs in nephrology, including treatments for dialysis-dependent and non-dialysis-dependent CKD patients.